Recurrent B Acute Lymphoblastic Leukemia Recruiting Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0107328 (Recurrent B Acute Lymphoblastic Leukemia)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02879695Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaTreatment